Interim / Quarterly Report • Dec 12, 2025
Interim / Quarterly Report
Open in ViewerOpens in native device viewer

The Group reported high order bookings, increased sales and profitability for the first half of 2025/2026. High levels of customer satisfaction resulted in new and expanded customer commitments, helping to further strengthen Sectra's market position in cybersecurity and medical imaging IT. This was especially the case in the US and Canada, important drivers underlying the positive performance of our medical operations.
Report presentation | December 12, 2025 at 10:00 a.m. (CET)
https://investor.sectra.com/q2report2526
Figures in parentheses pertain to the corresponding period/quarter in the preceding fiscal year.
| Key figures | Quarter | Period | 12 months | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SEK million | Q2 | Q2 | Δ | Q1–2 | Q1–2 | Δ | R12 | Full-year | Δ | |
| 25/26 | 24/25 | % | 25/26 | 24/25 | % | 25/26 | 24/25 | % | ||
| Contracted order bookings | 3,431.6 | 4,223.1 | -18.7 | 4,741.2 | 4,838.1 | -2.0 | 8,609.2 | 8,706.1 | -1.1 | |
| of which guaranteed order bookings | 2,246.0 | 4,017.0 | -44.1 | 3,438.3 | 4,560.1 | -24.6 | 6,531.2 | 7,653.0 | -14.7 | |
| Net sales | 850.6 | 753.5 | 12.9 | 1,616.4 | 1,477.3 | 9.4 | 3,378.9 | 3,239.8 | 4.3 | |
| of which recurring revenue | 587.9 | 484.7 | 21.3 | 1,137.1 | 967.0 | 17.6 | 2,237.5 | 2,067.4 | 8.2 | |
| of which cloud recurring revenue (CRR) | 212.2 | 121.3 | 74.9 | 391.7 | 244.1 | 60.5 | 738.7 | 591.1 | 25.0 | |
| Operating profit 2 | 188.6 | 109.6 | 72.1 | 307.4 | 209.4 | 46.8 | 821.1 | 723.0 | 13.6 | |
| excluding patent settlement | 188.6 | 109.6 | 72.1 | 307.4 | 209.4 | 46.8 | 711.1 | 613.0 | 16.0 | |
| Operating margin 2 , % |
22.2 | 14.5 | n/a | 19.0 | 14.2 | n/a | 24.3 | 22.3 | n/a | |
| excluding patent settlement, % | 22.2 | 14.5 | n/a | 19.0 | 14.2 | n/a | 21.0 | 18.9 | n/a | |
| Profit for the period 2 | 148.4 | 87.8 | 69.0 | 251.2 | 168.2 | 49.3 | 646.4 | 563.4 | 14.7 | |
| Churn, % | n/a | n/a | n/a | n/a | n/a | n/a | 0.5 | 0.6 | n/a | |
| Earnings per share, SEK 1, 2 | 0.77 | 0.46 | 67.4 | 1.30 | 0.87 | 49.4 | 3.35 | 2.92 | 14.7 | |
| Cash flow from operations | 41.4 | 176.1 | -76.5 | 159.6 | 119.4 | 33.7 | 962.6 | 922.4 | 4.4 | |
| Average no. of employees | 1,314 | 1,225 | 7.3 | 1,321 | 1,224 | 7.9 | 1,298 | 1,249 | 3.9 |
1Before and after dilution 2The outcomes for the full year and R12 include a patent settlement that had a positive impact of SEK 110 million on operating profit. The business transaction was a nonrecurring item and was recognized in its entirety during the third quarter of 2024/2025.

We live in dramatically and rapidly changing times, and as a wise Board member once said to me many years ago: "Where there is change, there is margin." It's simply a question of being faster than the competition. Our strength is based on the trust we have built over time. We have been quick to adopt new technology and seize new business opportunities, we have achieved the highest levels of customer satisfaction in the market and—not least—we have fantastic employees. This has resulted in loyal, returning customers, a growing order book and the market's leading solutions for managing essentially all medical images in the cloud.


Torbjörn Kronander, President and CEO
Our medical operations are growing with good profitability, contributing to a positive earnings trend in the face of continued currency headwinds. Our earnings for the second quarter received an extra boost from an agreement with a customer regarding compensation for delay, where the delay was not caused by Sectra. Several customers who signed comprehensive service contracts during the previous fiscal year have now entered the pilot phase. The focus is on optimizing services before major deployments. We expect to gradually increase the volumes from these contracts in the coming years. However, it is important to note that implementing these large projects will entail major increased costs, including costs for cloud computing, until our revenue starts to gain momentum after a quarter or two. This will have a negative impact on the rest of the fiscal year.
We are also experiencing product delivery delays in Secure Communications that will have a negative impact on the full year. Long development cycles and approval processes for encryption solutions as well as changing threat scenarios may have such effects. In the case of Secure Communications, these effects—which have been quite substantial—will continue for the rest of the fiscal year and are not expected to subside until next year. Otherwise this operating area has a strong positive trend, and we believe that the global security situation will continue to drive demand for products and services that can strengthen information security in society.
We have presented new products and features in all of our areas recently. In our security operations, this has involved making secure communication as a service available to a wider market, not least within the industry. In our medical operations, we participated in RSNA, the world's largest radiology conference, last week. We presented new features such as integrated and AI-supported diagnostic reporting and are the only PACS supplier to offer support for the important technology of photon-counting computed tomography directly in our workstations.
We are well positioned in relation to our competitors. We are still the only supplier with customers live with radiology, pathology, ophthalmology, cardiology and genomics modules in a consolidated, fully cloud-based diagnostics IT system. Integrated reporting is expected to be important in the future since it has the potential to drastically increase radiologist productivity. We are today the only PACS supplier to have diagnostic reporting integrated into medical imaging workstations.
The transition to selling cloud-based services is an investment in the future that requires persistence and a long-term focus. While this investment is putting pressure on our short-term financial performance, we are building a stronger and more resilient Sectra in the long term. Our strong financial position gives us the ability to invest in innovation and capacity for the future. One such innovative segment is within the area of genomics. Genomics IT, which is expected to have significant growth in the future, is where we today also have our most satisfied users. Together with our customers, we are shaping and driving the development towards a healthier and safer society.

Cloud services +61% recurring revenue y-o-y
Churn 0.5% of recurring revenue R12
High level of customer satisfaction
Sectra's overall operational target is to create significant customer value. Customers should be so satisfied with their experience that they remain for a long time, expand their use of our solutions and recommend Sectra to others. Delivering customer value is also the Group's most important sustainability target since our customers' work to treat patients and increase cybersecurity is essential for functioning societies.
Customer satisfaction requires satisfied and dedicated employees. Employees who are motivated, understand their customers and feel a sense of well-being will also increasingly develop new, creative solutions that can further increase the value we provide for Sectra's customers. Operating in markets that are growing, combined with satisfied customers and employees, provides a long-term sound financial performance.
Sectra has three Group-wide financial goals. Stability and profitability are considered fundamental goals. Once these goals have been met, the focus shifts to earnings growth per share, which in practice is our primary financial goal. All result indicators currently exceed the target levels by a comfortable margin despite the effects of changes in the business model. The financial goals are (in order of priority):

High level of quality and product safety
Sectra's pre-operative planning solution for orthopaedic trauma cases was expanded with 3D templates from Smith+Nephew, one of the world's leading medical equipment companies.
A contract for managed detection and response as a service for monitoring of critical infrastructure was signed with a new customer.
The 2025 Annual General Meeting (AGM) resolved on an ordinary and an extraordinary dividend, totaling SEK 404.6 million as well as authorizations, see page 12.

The Annual Meeting of the Radiological Society of North America (RSNA), an event held in Chicago in early December, brought together thousands of radiologists and decisionmakers from around the world. Sectra's booth was filled with visitors who learned more about our new products and features and discussed how we can work together to create more sustainable and efficient workflows and ease the workload of radiologists. Listen to some of our customers share how Sectra's solutions support efficiency, ensure stable operation and enable the use of AI in clinical work: https://youtu.be/vH1b_VlHCmM
Sectra plays a key role in meeting the need for medical imaging IT and cybersecurity. We help solve major social problems in changing markets, where scope for expansion remains. The global trends of an aging population and increased digitization mean that these markets are expected to continue to grow regardless of the economic climate. Information about trends and the company's markets can be found in Sectra's latest Annual Report and Sustainability Report.
Order bookings for the second quarter were Sectra's second-highest for a single quarter. They were only surpassed by the comparative quarter where Sectra won its largest order to date, a 12-year contract with MSSS Québec in Canada. Contracted order bookings for the six-month period decreased 2.0% to SEK 4,741.2 million (4,838.1), of which SEK 3,431.6 million (4,223.1) pertained to the second quarter. A total of SEK 3,438.3 million (4,560.1) was guaranteed order bookings, of which SEK 2,246.0 million (4,017.0) pertained to the second quarter.
The ratio of contracted order bookings to net sales for the latest rolling 12-month period totaled 2.6, compared with 2.7 at the end of the previous fiscal year. Order bookings often include comprehensive, long-term customer contracts. These are not signed every quarter and can lead to significant variations in order bookings between individual quarters and periods.
The Group's net sales rose 9.4% to SEK 1,616.4 million (1,477.3), of which SEK 850.6 million (753.5) pertained to the second quarter. Based on unadjusted exchange rates, consolidated sales increased 16.0% year-on-year.
The ongoing transition to selling products and software as services, of which cloud deliveries account for a quickly growing share, contributed to an increase in recurring revenue. SEK 1,137.1 million (967.0) of sales pertained to recurring revenue, of which SEK 587.9 million (484.7) pertained to the second quarter. This represents an increase of 17.6% year-on-year and an increase of 24.8% based on unadjusted exchange rates. Lost recurring revenue (recurring revenue churn) for the last 12-month period was 0.5%.
Cloud recurring revenue (CRR) rose 60.5% to SEK 391.7 million (244.1), of which SEK 212.2 million (121.3) pertained to the second quarter. Non-recurring revenue decreased to SEK 479.3 million (510.3), of which SEK 262.7 million (268.8) pertained to the second quarter. This was an expected consequence of the ongoing transition to service deliveries and this revenue varies significantly between quarters.
Imaging IT Solutions and Business Innovation contributed to the Group's sales growth during the six-month period. In geographic terms, the operations in the US reported the largest year-on-year sales increase. The UK reported growth in local currency. More than 70% of the Group's sales are carried out in foreign currency, primarily EUR, GBP and USD, which entails a relatively large sensitivity to currency fluctuations.

Sales trend per operating area, SEK million
Compared with the corresponding period of the preceding fiscal year

Sales trend per geographic market, SEK million
Compared with the corresponding period of the preceding fiscal


Sales (R12) by geographic market, SEK million

Growth in Sectra's medical operations, and investments in capitalizable development projects had a positive impact on operating profit and profitability. Compensation from a customer for delays in a project also had a positive impact on the outcome for the quarter. At the same time, exchange-rate movements dampened earnings, and delivery delays had a negative impact on the security operations. The Group's operating profit increased 46.8% to SEK 307.4 million (209.4), of which SEK 188.6 million (109.6) pertained to the second quarter. Based on unadjusted exchange rates, the year-on-year increase was 66.8%. The Group's operating margin amounted to 19.0% (14.2) for the six-month period. The outcome includes SEK 52.3 million (26.3) in costs for share-based incentive programs, of which SEK 16.2 million (13.8) pertained to the second quarter. The increase during the six-month period was due to a new program that started during the second half of 2024/2025, while the share price trend had a dampening effect on costs during the quarter.
The Group's financial items amounted to SEK 9.3 million (2.4), of which SEK -2.2 million (1.0) pertained to the second quarter. Currency fluctuations had a negative impact of SEK -0.5 million (-3.6) on the Group's financial items. Sectra does not hedge its operations, and currency fluctuations therefore have an immediate impact on profit or loss or on comprehensive income.
Profit after financial items amounted to SEK 316.7 million (211.8), of which SEK 186.4 million (110.5) pertained to the second quarter. This outcome corresponds to a profit margin of 19.6% (14.3) for the six-month period and 21.9% (14.7) for the second quarter. Earnings per share before and after dilution totaled SEK 1.30 (0.87) for the period, of which SEK 0.77 (0.46) pertained to the second quarter.
Operating profit trend per operating area, SEK million
Compared with the corresponding period of the preceding fiscal year.


The Group's cash and cash equivalents at the end of the reporting period amounted to SEK 1,016.5 million (625.8).
The Group's debt/equity ratio was 0.06 (0.06) as of the balance-sheet date. Interest-bearing lease liabilities amounted to SEK 95.1 million (91.9).
Cash flow from operations amounted to SEK 159.6 million (119.4) for the period, of which SEK 41.4 million (176.1) was attributable to the second quarter. While the increase in the period was the result of strong underlying earnings, the outcome was dampened by the settlement of current liabilities. The outcome for the second quarter was primarily impacted by an increase in capital tied up in current receivables.
Cash flow per share amounted to SEK 0.83 (0.62), of which SEK 0.22 (0.91) pertained to the second quarter.
Cash flow from investing activities amounted to SEK -70.3 million (-70.3), of which SEK -39.1 million (-27.2) pertained to the second quarter. Refer to the additional information about investments below.
The Group's total cash flow for the period amounted to SEK -328.4 million (-172.9). This result includes an ordinary and extraordinary dividend of SEK 404.6 million (211.9) to shareholders. The figure for the comparative period refers to Sectra's 2024 share redemption program.
Investments amounted to SEK 70.3 million (70.3), of which SEK 39.1 million (27.2) pertained to the second quarter. Capitalized work for own use amounted to SEK 50.6 million (32.3), of which SEK 27.6 million (19.4) pertained to the second quarter. Capitalization includes the development of cloud-based services for medical diagnostics.
Total depreciation/amortization amounted to SEK 56.4 million (53.5), of which SEK 28.9 million (27.3) pertained to the second quarter. Of the total depreciation/amortization for the period, SEK 26.0 million (22.3) was attributable to capitalized development expenditures, of which SEK 13.2 million (11.4) pertained to the second quarter. At the end of the period, capitalized development expenditures totaled SEK 259.0 million (212.7).
Sectra has historically experienced major seasonal variations, since individual projects can be very large relative to Sectra's sales. This applies for both medical systems and encryption systems. The beginning of the fiscal year is usually weaker since few customers want to deploy new systems during the summer. The variations in order volumes between individual quarters are significant since certain contracts are very large and have long terms.
As Sectra transitions to selling products as a service, this variation is expected to gradually decrease over the next several years since revenue will be spread more evenly over time. On the other hand, individual orders are sometimes very large, leading instead to a larger variation in order bookings than before.
Bearing this in mind, it remains important to look more at long-term trends rather than at the outcome for an individual quarter when assessing Sectra's performance. For further information about Sectra's seasonal patterns, refer to page 70 in Sectra's Annual and Sustainability Report for the 2024/2025 fiscal year.
Cash flow from operations for the Group, SEK million

Capitalized development expenditures, SEK million

| Quarter | P | Period | 12 months | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Q2 | Q2 | Δ | Q1–2 | Q1–2 | Δ | R12 | Full- year |
Δ | ||
| 25/26 | 24/25 | % | 25/26 | 24/25 | % | 25/26 | 24/25 | % | ||
| Sales, SEK million | 755.8 | 625.7 | 20.8 | 1,420.8 | 1,265.6 | 12.3 | 2,953.2 | 2,798.0 | 5.5 | |
| of which external recurring revenue | 550.7 | 447.5 | 23.1 | 1,064.0 | 896.4 | 18.7 | 2,092.4 | 1,924.8 | 8.7 | |
| of which cloud recurring revenue | 206.8 | 116.5 | 77.5 | 381.5 | 234.1 | 63.0 | 718.9 | 571.5 | 25.8 | |
| Operating profit, SEK million | 179.4 | 95.3 | 88.2 | 293.1 | 190.4 | 53.9 | 670.4 | 567.6 | 18.1 | |
| Operating margin, % | 23.7 | 15.2 | n/a | 20.6 | 15.0 | n/a | 22.7 | 20.3 | n/a |
Imaging IT Solutions won several large and medium-sized procurements during the first half of the year. These successes meant that Sectra's operations in its largest markets—the UK, Sweden and the US—more than doubled their contracted order bookings compared with the year-earlier period. However, these volumes did not quite reach the previous record-breaking level of the comparative period, which included a multiyear Canadian customer contract with a contracted order value of SEK 3.1 billion.
Use of Sectra's services for medical imaging is growing through deployment to new customers, add-on sales and healthcare providers choosing to convert from Sectra's on premises solutions to cloud services. The fastest-growing volumes were noted in North America, primarily in the US operations, which reported the largest sales growth in the first half of 2025/2026.
The increase in recurring revenue, which accounted for 75.3% of sales for the six-month period, confirms that the ongoing transition to becoming a service provider is moving forward. This is largely due to new customers going live with Sectra's cloud services as well as increased recurring revenue from traditional installations. Non-recurring revenue decreased from the comparative period, mainly as a result of customers switching to purchasing services instead of traditional software licenses. While the transition to the SaaS model will be advantageous over the long term, it could continue to cause the Group's financial performance to fluctuate in the short term and dampen its financial outcomes due to the reduction in initial license sales.
Increased sales meant that Imaging IT Solutions posted higher operating profit and profitability than in the comparative period. Increased investments in capitalizable development projects and lower consultant costs also had a positive impact on outcomes during the second quarter.
There are still numerous new customers who will go live with Sectra's cloud service for medical imaging during the fiscal year and in the coming years. Work to prepare for the deliveries is ongoing, and none of the largest customers are in full production yet. Revenue is growing as customers put the services into operation. Transitioning to services in the cloud represents a paradigm shift. The change processes involved in introducing cloud services require resources, both from Sectra's own operations and from customers' organizations. This means that in some cases, it may take several years for major customers to become fully operational and reach planned volumes. Allowing these installations to take time at the beginning will lead to high-quality deliveries and high levels of customer satisfaction.



| Quarter | Period | 12 months | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Q2 | Q2 | Δ | Q1-2 | Q1-2 | Δ | R12 | Full-year | Δ | |
| 25/26 | 24/25 | % | 25/26 | 24/25 | % | 25/26 | 24/25 | % | |
| Sales, SEK million | 29.4 | 18.8 | 56.4 | 51.6 | 36.4 | 41.8 | 106.0 | 90.8 | 16.7 |
| of which external recurring revenue | 6.1 | 5.5 | 10.9 | 11.4 | 11.3 | 0.9 | 23.3 | 23.2 | 0.4 |
| of which cloud recurring revenue | 5.5 | 4.8 | 14.6 | 10.2 | 10.0 | 2.0 | 19.7 | 19.5 | 1.0 |
| Operating profit/loss, SEK million | 6.0 | -1.5 | n/a | 7.6 | -1.8 | n/a | 19.3 | 9.9 | 94.9 |
| Operating margin, % | 20.4 | neg | n/a | 14.7 | neg | n/a | 18.2 | 10.9 | n/a |
Business Innovation comprises the Genomics IT, Medical Education and Orthopaedics business units. We also report the expenses for medical research activities in Business Innovation, which includes initiatives in the field of AI for medical applications. Sectra's research activities linked to secure communications are organized and reported in the Secure Communications operating area.
Business Innovation's operations are growing, and its sales and operating profit trends are positive. However, the results may vary significantly between quarters and periods. In the long term, subscription-based business models and growing volumes are expected to reduce quarterly variations.


Sectra has expanded its pre-operative planning solution for orthopaedic trauma cases with 3D templates from Smith+Nephew. The library of 3D templates in Sectra's planning tool now covers nearly 80% of the market for orthopaedic trauma surgery. This wide range is an important component of personalized treatment. Sectra's planning tool allows surgeons to prepare complex orthopaedic procedures with a high level of precision and safety, leading to better patient outcomes.
| Quarter | Pe | Period | 12 months | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Q2 25/26 |
Q2 24/25 |
Δ %_ |
Q1–2 25/26 |
Q1–2 24/25 |
Δ % |
R12 25/26 |
Full- year 24/25 |
Δ % |
||
| Sales, SEK million | 90.8 | 120.3 | -24.5 | 183.6 | 197.8 | -7.2 | 392.8 | 407.0 | -3.5 | |
| of which external recurring revenue | 31.2 | 31.3 | -0.3 | 61.7 | 58.6 | 5.3 | 121.8 | 118.7 | 2.6 | |
| Operating profit 1 , SEK million | 8.9 | 25.2 | -64.7 | 19.7 | 35.3 | -44.2 | 158.6 | 174.2 | -9.0 | |
| excl. patent settlement, SEK million | 8.9 | 25.2 | -64.7 | 19.7 | 35.3 | -44.2 | 48.6 | 64.2 | -24.3 | |
| Operating margin 1 , % | 9.8 | 20.9 | n/a | 10.7 | 17.8 | n/a | 40.4 | 42.8 | n/a | |
| excl. patent settlement, % | 9.8 | 20.9 | n/a | 10.7 | 17.8 | n/a | 12.4 | 15.8 | n/a |
<sup>1 The outcomes for the full year and R12 include a patent settlement that had a positive impact of SEK 110 million on operating profit. The business transaction was a nonrecurring item and was recognized in its entirety during the third quarter of 24/25.
The unstable global security situation is continuing to fuel the need for investments in high assurance products, encryption development and cybersecurity. Sectra is well positioned to respond to the needs of the market, with offerings that meet customers' stringent demands. Existing customers are continuing to increase their use of Sectra's products and services for secure mobile communication at the highest classification levels. Order bookings during the second quarter included additional orders of Sectra Tiger S and infrastructure and extensions of managed-services agreements. Defense customers have placed orders for further systems development and research assignments that will eventually lead to a more resilient society. A new customer in critical infrastructure also signed a contract for managed detection and response as a service.
The financial outcome for the operating area varies considerably between quarters, which is natural given the nature of the operations. The outcome for the most recent quarter was on par with the beginning of the fiscal year. The financial development was temporarily hampered by the fact that an ongoing development assignment in a major customer project was delayed due to revised requirements. This means that the contracted serial deliveries have also been delayed, with a plan to begin at the end of 25/26.
Sectra is also making extensive investments to strengthen and expand its ability to help customers protect their communication and critical infrastructure. For example, a new service—Sectra Tiger/E Managed Service—was launched after the quarter, expanding the target demographic for Sectra's offerings. The service can help organizations and businesses that process sensitive but formally unclassified information.
23/24
Sales, R12 —
Operating profit excl. patent settlement, R12 —
Operating profit incl. patent settlement, R12 —
24/25
25/26
Sectra Tiger/E Managed Service is the result of an investment in product development and packaging of Sectra's customer offerings within secure communication for a new area of use. The service targets authorities, municipalities, operations critical to society and businesses that need to communicate and protect sensitive information. The customer offering is a complement to Sectra's communication system for classified information.
The service supports voice and video calls, multi-party conference calls, messaging and chat. All with strong encryption, device security and a focus on high availability and ease-of-use. This allows users to be more flexible and mobile when handling all kinds of sensitive information, from trade secrets and daily operations to crisis management situations.

| Quarter | Period | 12 months | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 | Q2 | Δ | Q1–2 | Q1–2 | Δ | R12 | Full year |
Δ | |||
| 25/26 | 24/25 | % | 25/26 | 24/25 | % | 25/26 | 24/25 | % | |||
| Sales, SEK million | 77.2 | 53.7 | 43.8 | 145.2 | 101.0 | 43.8 | 261.0 | 216.9 | 20.3 | ||
| Operating loss, SEK million | -10.0 | -8.0 | -25.0 | -19.1 | -17.1 | -11.7 | -39.2 | -37.2 | -5.4 | ||
| Operating margin, % | neg | neg | n/a | neg | neg | n/a | neg | neg | n/a |
Other Operations pertain to Sectra's joint functions for administration, recruitment, Group finance, IT, regulatory affairs, people and brand, and activities related to investors. This segment also includes property management. The change from the comparative period mainly pertained to increased central management of costs distributed across the organization.
The Parent Company's income statement and balance sheet are reported on page 17. The Parent Company Sectra AB includes the research department for medical imaging IT, the Genomics IT business unit and the head office's joint functions (see Other Operations above).
The Board has decided to hold the AGM on September 8, 2026 in Linköping. The notice of the AGM is issued not earlier than six weeks and not later than four weeks prior to the AGM. Shareholders are entitled to have a matter addressed by the AGM. To ensure that the company has time to include matters in the notice, requests for matters to be addressed by the AGM should be received by the company not later than seven weeks prior to the AGM.
A Nomination Committee was appointed in accordance with the instructions adopted at the 2020 AGM. If any of the largest shareholders in terms of voting rights has waived their right to appoint a member of the Nomination Committee, the next shareholder in order of size has been given the opportunity to appoint a member. The Nomination Committee comprises the following members:
Sectra's share capital on the balance-sheet date totaled SEK 39,024,179, distributed between 195,120,895 shares and 313,052,035 votes. The number of shares is distributed between 13,103,460 Class A shares and 182,017,435 Class B shares. Sectra's holding of treasury shares at the end of the period amounted to 2,453,406 Class B shares, corresponding to 1.3% of the share capital and 0.8% of the voting rights in the company. For more information, refer to Note 3.
The Board of Directors was authorized by the 2025 AGM, during the period until the 2026 AGM, to decide on new share issues of a maximum of 18,500,000 Class B shares and to decide on the acquisition and divestment of the company's treasury shares, with the condition that the Company's holding of treasury shares at no point exceeds 10% of all the shares in the Company. At the time of publication of this financial report, the Board had not utilized these authorizations. The complete authorization is presented in the minutes from the AGM: https://investor.com/agm2025.
Through its operations, Sectra is exposed to such business risks as dependence on major customers and partners, the effect of currency fluctuations on pricing in the markets in which the Group is active, and property and liability risks. Sectra is also exposed to various types of financial risks such as currency, interest-rate, credit and liquidity risks. A detailed description of the risks and specific external factors as well as Sectra's strategies and tactics for minimizing risk exposure and limiting adverse effects are provided in the Administration Report in Sectra's Annual and Sustainability Report for the 2024/2025 fiscal year on pages 68–91 and in Note 30 on pages 119–120. No significant events have occurred that would alter the conditions reported.
Contact Sectra's CEO Torbjörn Kronander, telephone +46 13 23 52 27 or email [email protected].
Time: December 12, 2025 at 10:00 a.m. CET
Torbjörn Kronander, President and CEO of Sectra AB, and Jessica Holmquist, CFO of Sectra AB, will present the financial report and answer questions. The presentation will be held in English. For information about participating online or to listen to the recording afterwards, visit: https://investor.sectra.com/q2report2526.
Nine-month interim report March 6, 2026 at 8:15 a.m. (CET) Year-end report June 5, 2026 at 8:15 a.m. (CEST) Annual General Meeting September 8, 2026 at 3:30 p.m. (CEST)
For further information about IR events, visit https://investor.sectra.com/events-and-presentations/
The Board of Directors and the President of Sectra AB (publ) hereby assure that the interim report from May 1–October 31, 2025 provides a true and fair view of the Parent Company's and Group's operations, financial position and earnings and describes the significant risks and uncertainties facing the Parent Company and other companies in the Group.
The contents of this interim report were decided on December 11, 2025
Linköping, December 11, 2025
Torbjörn Kronander Jan-Olof Brüer Tomas Puusepp President, CEO and Board member Chairman Board member
Ulrika Unell Anders Persson Fredrik Robertsson Board member Board member Board member
Birgitta Hagenfeldt Alva Mårdsjö Olof Sandberg Board member Board member and Board member and employee representative employee representative
This report was not reviewed by the company's auditor.
This information constitutes information that Sectra AB (publ) is obligated to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of Sectra's contact person set out above, at 8:15 a.m. (CET) on December 12, 2025.
Sectra AB (publ), Corporate Registration Number 556064-8304, https://sectra.com, email [email protected]
| 3 months | 3 months | 6 months | 6 months | 12 months | Full-year |
|---|---|---|---|---|---|
| Aug–Oct | Aug–Oct | May–Oct | May–Oct | Nov 2024 | May–Apr |
| 2025 | 2024 | 2025 | 2024 | –Oct 2025 | 2024/2025 |
| 850,583 | 753,500 | 1,616,437 | 1,477,336 | 3,378,912 | 3,239,811 |
| 27,584 | 19,385 | 50,591 | 32,299 | 92,385 | 74,093 |
| 25,313 | 6,519 | 32,437 | 9,248 | 249,545 | 226,356 |
| 903,480 | 779,404 | 1,699,465 | 1,518,883 | 3,720,842 | 3,540,260 |
| -441,712 | |||||
| -1,598,697 | |||||
| -665,324 | |||||
| -28,874 | -27,339 | -56,446 | -53,487 | -114,489 | -111,530 |
| -714,840 | -669,837 | -1,392,025 | -1,309,502 | -2,899,786 | -2,817,263 |
| 188,640 | 109,567 | 307,440 | 209,381 | 821,056 | 722,997 |
| -2,199 | 960 | 9,301 | 2,406 | 10,179 | 3,284 |
| 186,441 | 110,527 | 316,741 | 211,787 | 831,235 | 726,281 |
| -38,043 | -22,768 | -65,558 | -43,628 | -184,840 | -162,910 |
| 148,399 | 87,759 | 251,183 | 168,159 | 646,395 | 563,371 |
| 148,399 | 87,759 | 251,183 | 168,159 | 646,395 | 563,371 |
| -109,774 -420,058 -156,134 |
-120,734 -385,530 -136,234 |
-214,967 -840,368 -280,244 |
-224,019 -765,674 -266,322 |
-432,660 -1,673,391 -679,246 |
1 The outcome for full-year 2024/2025 includes the patent settlement of SEK 195 million.
| SEK thousand | 3 months | 3 months | 6 months | 6 months | 12 months | Full-year |
|---|---|---|---|---|---|---|
| Aug–Oct | Aug–Oct | May–Oct | May–Oct | Nov 2024 | May–Apr | |
| 2025 | 2024 | 2025 | 2024 | –Oct 2025 | 2024/2025 | |
| Profit for the period | 148,399 | 87,759 | 251,183 | 168,159 | 646,395 | 563,371 |
| Items that may be reversed in profit or loss |
||||||
| Translation differences | -19,011 | -5,296 | -9,925 | -8,745 | -48,707 | -47,527 |
| Total other comprehensive income for the period |
-19,011 | -5,296 | -9,925 | -8,745 | -48,707 | -47,527 |
| Total comprehensive income for the period |
129,388 | 82,463 | 241,258 | 159,414 | 597,688 | 515,844 |
| Comprehensive income for the period attributable to: |
||||||
| Parent Company owners | 129,388 | 82,463 | 241,258 | 159,414 | 597,688 | 515,844 |
| Total equity and liabilities | 3,500,148 | 3,190,365 | 3,756,229 |
|---|---|---|---|
| Total current liabilities | 1,540,318 | 1,532,839 | 1,701,450 |
| Other current liabilities Accrued expenses and deferred income |
240,084 1,270,199 |
181,792 1,328,527 |
263,267 1,408,947 |
| Current lease liabilities | 24,557 | 20,595 | 23,617 |
| Provisions | 5,478 | 1,925 | 5,619 |
| Total long-term liabilities | 170,194 | 125,291 | 137,954 |
| Other long-term liabilities | 11,949 | - | 11,733 |
| Non-current lease liabilities | 70,530 | 71,314 | 63,840 |
| Provisions | 83,477 | 47,145 | 58,318 |
| Deferred tax liabilities | 4,238 | 6,832 | 4,063 |
| Equity | 1,789,636 | 1,532,235 | 1,916,825 |
| Equity and liabilities | |||
| Total assets | 3,500,148 | 3,190,365 | 3,756,229 |
| Total current assets | 2,623,798 | 2,408,703 | 2,959,131 |
| Cash and bank balances | 1,016,471 | 625,776 | 1,341,871 |
| Prepaid expenses and accrued income | 911,591 | 1,113,712 | 938,732 |
| Other current assets | 131,957 | 94,878 | 106,492 |
| Accounts receivable | 563,779 | 574,337 | 572,036 |
| Total fixed assets | 876,350 | 781,662 | 797,098 |
| Deferred tax assets | 9,193 | 8,858 | 8,502 |
| Financial assets | 227,133 | 161,090 | 178,464 |
| Right-of-use assets | 112,154 | 114,514 | 106,415 |
| Tangible assets | 219,654 | 226,616 | 220,654 |
| Intangible assets and goodwill | 308,216 | 270,584 | 283,063 |
| Assets | |||
| SEK thousand | Oct 31, 2025 |
Oct 31, 2024 |
Apr 30, 2025 |
| SEK thousand | 6 months | 6 months | Full-year |
|---|---|---|---|
| May–Oct | May–Oct | May–Apr | |
| 2025 | 2024 | 2024/2025 | |
| Operating activities | |||
| Operating profit | 307,440 | 209,381 | 722,997 |
| Adjustment for non-cash items | 115,777 | 98,908 | 179,581 |
| Interest received | 13,240 | 7,772 | 31,403 |
| Interest paid | -3,465 | -1,790 | -4,308 |
| Income tax paid | -110,981 | -116,500 | -171,703 |
| Cash flow from operations before changes in working capital | 322,011 | 197,771 | 757,970 |
| Changes in working capital | |||
| Change in inventories | -2,421 | 3,897 | -1,108 |
| Change in receivables | -26,656 | -55,133 | -16,367 |
| Change in current liabilities | -133,357 | -27,184 | 181,869 |
| Cash flow from operations | 159,577 | 119,351 | 922,364 |
| Investing activities | |||
| Acquisitions of intangible assets | -53,767 | -32,300 | -75,237 |
| Acquisitions of tangible assets | -16,518 | -37,992 | -34,755 |
| Acquisition of financial assets | - | - | -3,872 |
| Cash flow from investing activities | -70,285 | -70,292 | -113,864 |
| Financing activities | |||
| Repayment of lease liabilities | -13,084 | -10,021 | -39,950 |
| Dividend/redemption of shares | -404,602 | -211,935 | -211,935 |
| Cash flow from financing activities | -417,686 | -221,956 | -251,885 |
| Cash flow for the period | -328,394 | -172,897 | 556,615 |
| Cash and cash equivalents, opening balance | 1,341,871 | 804,640 | 804,640 |
| Exchange-rate difference in cash and cash equivalents | 2,994 | -5,967 | -19,384 |
| Cash and cash equivalents, closing balance | 1,016,471 | 625,776 | 1,341,871 |
| Equity at end of period | 1,789,636 | 1,532,235 | 1,916,825 |
|---|---|---|---|
| Share-based payments | 36,155 | 15,165 | 43,325 |
| Dividend/redemption of shares | -404,602 | -211,935 | -211,935 |
| Comprehensive income for the period | 241,258 | 159,414 | 515,844 |
| Equity at start of period | 1,916,825 | 1,569,591 | 1,569,591 |
| 2025 | 2024 | 2024/2025 | |
| May–Oct | May–Oct | May–Apr | |
| SEK thousand | 6 months | 6 months | Full-year |
| SEK thousand | 3 months | 3 months | 6 months | 6 months | 12 months | Full-year |
|---|---|---|---|---|---|---|
| Aug–Oct | Aug–Oct | May–Oct | May–Oct | Nov 2024 | May–Apr | |
| 2025 | 2024 | 2025 | 2024 | –Oct 2025 | 2024/2025 | |
| Net sales | 79,905 | 53,967 | 148,994 | 101,323 | 270,853 | 223,182 |
| Capitalized work for own use | 0 | 1,022 | 0 | 2,244 | 573 | 2,817 |
| Other operating income | 16,128 | 15 | 18,584 | 32 | 25,357 | 6,805 |
| Total income | 96,033 | 55,004 | 167,578 | 103,599 | 296,783 | 232,804 |
| Goods for resale | -31,636 | -11,173 | -54,450 | -21,750 | -88,317 | -55,617 |
| Personnel costs | -25,647 | -19,710 | -45,931 | -37,305 | -91,909 | -83,283 |
| Other external costs | -55,505 | -34,121 | -95,671 | -66,108 | -171,849 | -142,286 |
| Depreciation/amortization | -1,089 | -455 | -2,146 | -901 | -3,060 | -1,815 |
| Total operating expenses | -113,877 | -65,459 | -198,198 | -126,064 | -355,135 | -283,001 |
| Operating loss | -17,844 | -10,455 | -30,620 | -22,465 | -58,352 | -50,197 |
| Total financial items | 65,166 | 86,054 | 71,708 | 87,525 | 80,162 | 95,979 |
| Profit after financial items | 47,322 | 75,599 | 41,088 | 65,060 | 21,810 | 45,782 |
| Appropriations | - | - | - | - | 542,000 | 542,000 |
| Profit before tax | 47,322 | 75,599 | 41,088 | 65,060 | 563,810 | 587,782 |
| Tax on earnings for the period | - | - | - | - | -104,356 | -104,356 |
| Profit for the period | 47,322 | 75,599 | 41,088 | 65,060 | 459,454 | 483,427 |
| 2025 | 2024 | 2025 | 2024 | –Oct 2025 | 2024/2025 | |
| Profit for the period | 47,322 | 75,599 | 41,088 | 65,060 | 459,454 | 483,427 |
| Total comprehensive income for the | ||||||
| period | 47,322 | 75,599 | ||||
| 41,088 | 65,060 | 459,454 | ||||
| Oct 31, 2025 |
Oct 31, 2024 |
|||||
| 10,800 | 11,427 | |||||
| 8,212 | 7,392 | |||||
| 326,706 | 379,813 | |||||
| 345,718 | 398,632 | |||||
| 15,001 | 1,118 | |||||
| 581,647 | 675,092 | |||||
| 54,754 | 32,961 | |||||
| 858,557 | 503,011 | |||||
| 1,509,959 1,855,677 |
1,212,182 1,610,814 |
|||||
| Condensed Parent Company balance sheets SEK thousand Assets Intangible assets Tangible assets Financial assets Total fixed assets Accounts receivable Receivables from Group companies Other current assets Cash and bank balances Total current assets Total assets |
||||||
| 276,280 | 276,707 | 483,427 Apr 30, 2025 12,000 6,975 330,409 349,384 9,190 1,113,990 41,474 1,145,466 2,310,120 2,659,504 277,480 |
||||
| 766,769 | 647,312 | 1,093,723 | ||||
| Equity and liabilities Restricted equity Unrestricted equity Total equity |
1,043,049 | 924,019 | 1,371,203 |
Provisions 10,005 3,453 6,327 Current liabilities 802,623 683,342 1,281,974 Total equity and liabilities 1,855,677 1,610,814 2,659,504
This interim report has been prepared in accordance with IAS 34 Interim Financial Reporting, the Swedish Annual Accounts Act and the Swedish Securities Markets Act. The accounting policies and calculation methods applied are consistent with those described in Sectra's 2024/2025 Annual and Sustainability Report.
Other than the types of transactions presented in Note 3 Employees and personnel costs in the 2024/2025 Annual Report, no significant transactions with related parties took place in the reporting period.
| No. of common shares 1, 2 | 3 months Aug–Oct 2025 |
3 months Aug–Oct 2024 |
6 months May–Oct 2025 |
6 months May–Oct 2024 |
12 months Nov 2024 –Oct 2025 |
Full-year May–Apr 2024/2025 |
|---|---|---|---|---|---|---|
| At the end of the period | 192,667,489 | 192,667,489 | 192,667,489 | 192,667,489 | 192,667,489 | 192,667,489 |
| Average | 192,667,489 | 192,667,489 | 192,667,489 | 192,667,489 | 192,667,489 | 192,667,489 |
1 Before and after dilution.
| SEK million | 3 months | 3 months | 6 months | 6 months | 12 months | Full-year |
|---|---|---|---|---|---|---|
| Aug–Oct | Aug–Oct | May–Oct | May–Oct | Nov 2024 | May–Apr | |
| 2025 | 2024 | 2025 | 2024 | –Oct 2025 | 2024/2025 | |
| Imaging IT Solutions | 755.8 | 625.7 | 1,420.8 | 1,265.6 | 2,953.2 | 2,798.0 |
| Secure Communications | 90.8 | 120.3 | 183.6 | 197.8 | 392.8 | 407.0 |
| Business Innovation | 29.4 | 18.8 | 51.6 | 36.4 | 106.0 | 90.8 |
| Other Operations | 77.2 | 53.7 | 145.2 | 101.0 | 261.0 | 216.9 |
| Group eliminations | -102.6 | -65.0 | -184.8 | -123.5 | -334.1 | -272.9 |
| Total | 850.6 | 753.5 | 1,616.4 | 1,477.3 | 3,378.9 | 3,239.8 |
| SEK million | 3 months | 3 months | 6 months | 6 months | 12 months | Full-year |
|---|---|---|---|---|---|---|
| Aug–Oct | Aug–Oct | May–Oct | May–Oct | Nov 2024 | May–Apr | |
| 2025 | 2024 | 2025 | 2024 | –Oct 2025 | 2024/2025 | |
| Imaging IT Solutions | 179.4 | 95.3 | 293.1 | 190.4 | 670.4 | 567.6 |
| Secure Communications | 8.9 | 25.2 | 19.7 | 35.3 | 158.6 | 174.2 |
| Business Innovation | 6.0 | -1.5 | 7.6 | -1.8 | 19.3 | 9.9 |
| Other Operations | -10.0 | -8.0 | -19.1 | -17.1 | -39.2 | -37.2 |
| Group eliminations | 4.3 | -1.4 | 6.1 | 2.6 | 12.0 | 8.5 |
| Total | 188.6 | 109.6 | 307.4 | 209.4 | 821.1 | 723.0 |
| SEK million | 3 months | 3 months | 6 months | 6 months | 12 months | Full-year |
|---|---|---|---|---|---|---|
| Aug–Oct | Aug–Oct | May–Oct | May–Oct | Nov 2024 | May–Apr | |
| 2025 | 2024 | 2025 | 2024 | –Oct 2025 | 2024/2025 | |
| United States | 277.9 | 181.4 | 488.3 | 360.4 | 1,027.4 | 899.5 |
| Sweden | 150.1 | 170.4 | 302.1 | 303.3 | 626.7 | 627.9 |
| United Kingdom | 140.1 | 143.3 | 295.2 | 300.0 | 608.7 | 613.5 |
| Rest of Europe | 205.1 | 201.9 | 391.2 | 389.1 | 829.9 | 827.8 |
| Rest of World | 77.4 | 56.5 | 139.6 | 124.5 | 286.2 | 271.1 |
| Total | 850.6 | 753.5 | 1,616.4 | 1,477.3 | 3,378.9 | 3,239.8 |
2Number of shares does not include the 2,453,406 (1,453,406) Class B treasury shares.
| Group | 3 months | 3 months | 6 months | 6 months | 12 months | Full-year |
|---|---|---|---|---|---|---|
| SEK million | Aug–Oct | Aug–Oct | May–Oct | May–Oct | Nov 2024 | May–Apr |
| 2025 | 2024 | 2025 | 2024 | –Oct 2025 | 2024/2025 | |
| Recurring revenue | 587.9 | 484.7 | 1,137.1 | 967.0 | 2,237.5 | 2,067.4 |
| Of which cloud recurring revenue, CRR | 212.2 | 121.3 | 391.7 | 244.1 | 738.7 | 591.1 |
| Non-recurring revenue | 262.7 | 268.8 | 479.3 | 510.3 | 1,141.4 | 1,172.4 |
| Total | 850.6 | 753.5 | 1,616.4 | 1,477.3 | 3,378.9 | 3,239.8 |
| Share of recurring revenue, % | 69.1 | 64.3 | 70.3 | 65.5 | 66.2 | 63.8 |
| Imaging IT Solutions | ||||||
| SEK million | 3 months | 3 months | 6 months | 6 months | 12 months | Full-year |
| Aug–Oct 2025 |
Aug–Oct 2024 |
May–Oct 2025 |
May–Oct 2024 |
Nov 2024 –Oct 2025 |
May–Apr 2024/2025 |
|
| Recurring revenue | 550.7 | 447.5 | 1,064.0 | 896.4 | 2,092.4 | 1,924.8 |
| Of which cloud recurring revenue, CRR | 206.8 | 116.5 | 381.5 | 234.1 | 718.9 | 571.5 |
| Non-recurring revenue | 196.7 | 176.5 | 348.5 | 366.5 | 849.9 | 867.9 |
| Total | 747.4 | 624.0 | 1,412.5 | 1,262.9 | 2,942.3 | 2,792.7 |
| Share of recurring revenue, % | 73.7 | 71.7 | 75.3 | 71.0 | 71.1 | 68.9 |
| Secure Communications | ||||||
| SEK million | 3 months | 3 months | 6 months | 6 months | 12 months | Full-year |
| Aug–Oct 2025 |
Aug–Oct 2024 |
May–Oct 2025 |
May–Oct 2024 |
Nov 2024 –Oct 2025 |
May–Apr 2024/2025 |
|
| Recurring revenue | 31.2 | 31.3 | 61.7 | 58.6 | 121.8 | 118.7 |
| Of which cloud recurring revenue, CRR | - | - | - | - | - | - |
| Non-recurring revenue | 59.6 | 88.6 | 121.9 | 138.6 | 271.0 | 287.7 |
| Total | 90.8 | 119.9 | 183.6 | 197.2 | 392.8 | 406.4 |
| Share of recurring revenue, % | 34.4 | 26.1 | 33.6 | 29.7 | 31.0 | 29.2 |
| Business Innovation | ||||||
| SEK million | 3 months | 3 months | 6 months | 6 months | 12 months | Full-year |
| Aug–Oct 2025 |
Aug–Oct 2024 |
May–Oct 2025 |
May–Oct 2024 |
Nov 2024 –Oct 2025 |
May–Apr 2024/2025 |
|
| Recurring revenue | 6.1 | 5.5 | 11.4 | 11.3 | 23.3 | 23.2 |
| Of which cloud recurring revenue, CRR | 5.5 | 4.8 | 10.2 | 10.0 | 19.7 | 19.5 |
| Non-recurring revenue | 6.3 | 2.8 | 8.9 | 4.0 | 21.7 | 16.8 |
| Total | 12.4 | 8.3 | 20.3 | 15.3 | 45.0 | 40.0 |
| Share of recurring revenue, % | 49.2 | 66.3 | 56.2 | 73.9 | 51.8 | 58.0 |
| Other Operations | ||||||
| SEK million | 3 months | 3 months | 6 months | 6 months | 12 months | Full-year |
| Aug–Oct 2025 |
Aug–Oct 2024 |
May–Oct 2025 |
May–Oct 2024 |
Nov 2024 –Oct 2025 |
May–Apr 2024/2025 |
|
| Recurring revenue | 0.0 | 0.3 | 0.0 | 0.6 | 0.1 | 0.7 |
| Of which cloud recurring revenue, CRR | - | - | - | - | - | - |
| Non-recurring revenue | 0.0 | 1.1 | 0.0 | 1.3 | 0.0 | 0.0 |
| Total | 0.0 | 1.4 | 0.0 | 1.9 | 0.1 | 0.7 |
| Share of recurring revenue, % | 100.0 | 21.4 | 100.0 | 31.6 | 100.0 | 100.0 |
The Group applies the European Securities and Markets Authority (ESMA) Guidelines on Alternative Performance Measures. Alternative performance measures are applied since the company believes they provide valuable supplementary information for management and investors given that they play a central role when it comes to understanding and evaluating the Group's operations.
Shows the portion of external sales that is recurring. Recurring revenue refers to revenue from customers for the provision of a good or service during the term of a contract, wherein the customer cannot continue to benefit from the full functionality of the good or service without ongoing payments and the revenue stream is expected to recur for more than 12 months.
Recurring revenue mainly refers to revenue from subscription, support and maintenance agreements. The share delivered via the cloud is reported as cloud recurring revenue (CRR). Revenue from system implementations, migration and one-time purchases of licenses are not recognized as recurring revenue.
Recurring revenue divided by total external sales. Refer to Note 4.
Recurring revenue churn
| SEK thousand | 12 months | Full-year |
|---|---|---|
| Nov 2024 | May–Apr | |
| –Oct 2025 | 2024/2025 | |
| Recurring revenue from customer contracts that have concluded or not been | ||
| renewed | 12,280 | 12,972 |
| Recurring revenue | 2,237,450 | 2,067,354 |
| Recurring revenue churn, % | 0.5 | 0.6 |
Indicates the share of recurring revenue from customer contracts that have concluded or not been renewed during the latest rolling 12-month period.
Recurring revenue from customer contracts that have concluded or not been renewed divided by total recurring revenue.
Equity per share before and after dilution
| SEK | 9.29 | 7.95 | 9.95 |
|---|---|---|---|
| Equity per share before and after dilution, | |||
| the end of the period | 192,667,489 | 192,667,489 | 192,667,489 |
| Number of shares before and after dilution at | |||
| Equity, SEK thousand | 1,789,636 | 1,532,235 | 1,916,825 |
| Oct 31, 2025 |
Oct 31, 2024 |
Apr 30, 2025 |
Measures the company's net value per share and shows the change in shareholder capital per share over time.
Equity divided by the number of shares before and after dilution at the end of the period.
| SEK thousand | Oct 31, | Oct 31, | Apr 30, |
|---|---|---|---|
| 2025 | 2024 | 2025 | |
| Non-interest-bearing liabilities | 1,603,476 | 1,566,221 | 1,740,213 |
| Interest-bearing liabilities | 107,036 | 91,909 | 99,190 |
| Total liabilities | 1,710,512 | 1,658,130 | 1,839,403 |
Indicates the proportion of the Company's liabilities with and without interest. Included in the calculation of the debt/equity ratio and capital employed.
Non-interest-bearing liabilities refers to liabilities without interest, such as accounts payable, advances from customers and tax liabilities. Interestbearing liabilities refers to liabilities with interest, such as lease liabilities.
| dilution, SEK | 0.22 | 0.91 | 0.83 | 0.62 | 5.00 | 4.79 |
|---|---|---|---|---|---|---|
| Cash flow per share before and after | ||||||
| at the end of the period | 192,667,489 | 192,667,489 | 192,667,489 | 192,667,489 | 192,667,489 | 192,667,489 |
| Number of shares before and after dilution | ||||||
| Cash flow from operations, SEK thousand | 41,438 | 176,068 | 159,577 | 119,351 | 962,590 | 922,364 |
| Aug–Oct 2025 |
Aug–Oct 2024 |
May–Oct 2025 |
May–Oct 2024 |
Nov 2024 –Oct 2025 |
May–Apr 2024/2025 |
|
| 3 months | 3 months | 6 months | 6 months | 12 months | Full-year |
Shows the cash flow the company generated per share before capital investments and financing.
Cash flow from operations divided by the number of shares before and after dilution at the end of the period.
Ratio of contracted order bookings to net sales
| Ratio of contracted order bookings to net sales | 2.55 | 2.69 |
|---|---|---|
| Net sales | 3,378,912 | 3,239,811 |
| Contracted order bookings | 8,609,152 | 8,706,063 |
| SEK thousand | 12 months Nov 2024 –Oct 2025 |
May–Apr 2024/2025 |
| Full-year |
Provides an indication of demand for the company's products and services.
Contracted order bookings divided by net sales.
Liquidity
| Liquidity | 1.7 | 1.6 | 1.7 |
|---|---|---|---|
| Current liabilities | 1,540,318 | 1,532,839 | 1,701,450 |
| Unutilized overdraft facilities | 15,000 | 15,000 | 15,000 |
| Current assets | 2,623,798 | 2,408,703 | 2,959,131 |
| SEK thousand | Oct 31, 2025 |
Oct 31, 2024 |
Apr 30, 2025 |
Shows the company's current ability to pay. Current assets plus unutilized overdraft facility divided by current liabilities.
Purpose Calculation
Shows full-time positions in a certain period. Average number of full-time employees during the period.
Unadjusted exchange rates – sales
| 3 months Aug–Oct 2025 |
3 months Aug–Oct 2024 |
6 months May–Oct 2025 |
6 months May–Oct 2024 |
Full-year May–Apr 2024/2025 |
|
|---|---|---|---|---|---|
| Nominal change, % | 12.9 | -4.3 | 9.4 | 7.7 | 9.3 |
| Exchange-rate effect, % | 6.9 | 2.2 | 6.6 | 1.6 | 0.9 |
| Change in unadjusted exchange rates, % | 19.8 | -2.1 | 16.0 | 9.3 | 10.2 |
Provides an indication of changes in financial measures for unadjusted exchange rates.
Amounts for the current year restated at last year's average exchange rates less last year's amounts at last year's average exchange rates, divided by last year's amounts at last year's rates. Unadjusted exchange rates – operating profit
| 3 months Aug–Oct 2025 |
3 months Aug–Oct 2024 |
6 months May–Oct 2025 |
6 months May–Oct 2024 |
Full-year May–Apr 2024/2025 |
|
|---|---|---|---|---|---|
| Nominal change, % | 72.1 | -38.0 | 46.8 | -14.9 | 39.6 |
| Exchange-rate effect, % | 22.9 | 2.8 | 20.0 | 2.5 | 1.9 |
| Change in unadjusted exchange rates, % | 95.0 | -35.2 | 66.8 | -12.4 | 41.5 |
Provides an indication of changes in financial measures for unadjusted exchange rates. Disclosures and adjustments of the effects of non-recurring transactions in operating profit and operating margin are made separately. When applicable, information about such transactions is provided on page 1.
Amounts for the current year restated at last year's average exchange rates less last year's amounts at last year's average exchange rates, divided by last year's amounts at last year's rates.
| 3 months | 3 months | 6 months | 6 months | Full-year | |
|---|---|---|---|---|---|
| Aug–Oct | Aug–Oct | May–Oct | May–Oct | May–Apr | |
| 2025 | 2024 | 2025 | 2024 | 2024/2025 | |
| Nominal change, % | 21.3 | 12.8 | 17.6 | 17.0 | 19.9 |
| Exchange-rate effect, % | 7.6 | 2.4 | 7.2 | 1.5 | 0.8 |
| Change in unadjusted exchange rates, % | 28.9 | 15.2 | 24.8 | 18.5 | 20.7 |
Provides an indication of changes in financial measures for unadjusted exchange rates.
Amounts for the current year restated at last year's average exchange rates less last year's amounts at last year's average exchange rates, divided by last year's amounts at last year's rates.
Indicates future revenue in the company. The share of contracted order bookings that corresponds to what the customer has undertaken to purchase when the contract is entered into.
Indicates future revenue in the company. The value of orders received that corresponds to what the customer has procured and intends to purchase during the term of the contract.
| Earnings per share for the rolling 12-month period P/E ratio, multiple |
3.35 90.1 |
2.92 101.6 |
|---|---|---|
| Share price at end of period | 301.80 | 296.60 |
| Nov 2024 –Oct 2025 |
May–Apr 2024/2025 |
|
| SEK | 12 months | Full-year |
Shows how the market values the company's profits and how long it may take for the shareholders to get a return on an investment in the share.
Share price at the end of the period divided by earnings per share for the most recent rolling 12-month period before dilution.
Earnings per share before and after dilution
| Profit for the period, SEK thousand Average number of shares before and after dilution |
148,399 192,667,489 |
87,759 192,667,489 |
251,183 192,667,489 |
168,159 192,667,489 |
646,395 192,667,489 |
563,371 192,667,489 |
|---|---|---|---|---|---|---|
| Earnings per share before and after dilution, SEK |
0.77 | 0.46 | 1.30 | 0.87 | 3.35 | 2.92 |
Shows each share's participation in the company's earnings during the reporting period.
Profit/loss after tax divided by the average number of shares before or after dilution. This performance measure is defined in accordance with IFRS.
| Return on equity, % | 7.7 | 5.5 | 13.6 | 10.8 | 38.9 | 32.3 |
|---|---|---|---|---|---|---|
| Average equity | 1,918,200 | 1,593,228 | 1,853,231 | 1,550,913 | 1,660,936 | 1,743,208 |
| Equity at end of period | 1,789,636 | 1,532,235 | 1,789,636 | 1,532,235 | 1,789,636 | 1,916,825 |
| Equity at start of period | 2,046,764 | 1,654,220 | 1,916,825 | 1,569,591 | 1,532,235 | 1,569,591 |
| Profit for the period | 148,399 | 87,759 | 251,183 | 168,159 | 646,395 | 563,371 |
| SEK thousand | 3 months Aug–Oct 2025 |
3 months Aug–Oct 2024 |
6 months May–Oct 2025 |
6 months May–Oct 2024 |
12 months Nov 2024 –Oct 2025 |
Full-year May–Apr 2024/2025 |
Shows the return on capital attributable to the Parent Company owners.
Profit for the period divided by average equity.
| SEK thousand | 3 months | 3 months | 6 months | 6 months | 12 months | Full-year |
|---|---|---|---|---|---|---|
| Aug–Oct 2025 |
Aug–Oct 2024 |
May–Oct 2025 |
May–Oct 2024 |
Nov 2024 –Oct 2025 |
May–Apr 2024/2025 |
|
| Profit after financial items | 186,441 | 110,527 | 316,741 | 211,787 | 831,235 | 726,281 |
| Financial expenses | -2,125 | -1,228 | -3,465 | -1,790 | -5,984 | -4,308 |
| Average capital employed | 2,026,180 | 1,662,124 | 1,956,344 | 1,612,761 | 1,760,408 | 1,808,698 |
| Return on capital employed, % | 9.3 | 6.7 | 16.4 | 13.2 | 47.6 | 40.4 |
Shows profitability based on how much capital is used in the operations.
Profit after financial items plus financial expenses divided by average capital employed.
| Operating margin, % | 22.2 | 14.5 | 19.0 | 14.2 | 24.3 | 22.3 |
|---|---|---|---|---|---|---|
| Net sales | 850,583 | 753,500 | 1,616,437 | 1,477,336 | 3,378,912 | 3,239,811 |
| Operating profit | 188,640 | 109,567 | 307,440 | 209,381 | 821,056 | 722,997 |
| SEK thousand | 3 months Aug–Oct 2025 |
3 months Aug–Oct 2024 |
6 months May–Oct 2025 |
6 months May–Oct 2024 |
12 months Nov 2024 –Oct 2025 |
Full-year May–Apr 2024/2025 |
Measures operational profitability. This measure is used for the purpose of management by objectives in the operations. Disclosures and adjustments of the effects of non-recurring transactions in operating profit and operating margin are made separately. When applicable, information about such transactions is provided on page 1.
Operating profit divided by net sales.
Operating profit per share
| 12 months | Full-year | |
|---|---|---|
| Nov 2024 | May–Apr | |
| –Oct 2025 | 2024/2025 | |
| Operating profit, SEK thousand | 821,056 | 722,997 |
| Number of shares before dilution | 192,667,489 | 192,667,489 |
| Operating profit per share, SEK | 4.26 | 3.75 |
Shows earnings per share before interest and taxes. Disclosures and adjustments of the effects of non-recurring transactions in operating profit are made separately. When applicable, information about such transactions is provided on page 1.
Operating profit divided by the number of shares before dilution on the balance-sheet date.
Debt/equity ratio
| SEK thousand | Oct 31, | Oct 31, | Apr 30, |
|---|---|---|---|
| 2025 | 2024 | 2025 | |
| Interest-bearing liabilities | 107,036 | 91,909 | 99,190 |
| Equity | 1,789,636 | 1,532,235 | 1,916,825 |
| Debt/equity ratio | 0.06 | 0.06 | 0.05 |
Shows to what extent the operations are financed by loans and describes the company's financial risk.
Interest-bearing liabilities divided by equity.
Equity/assets ratio
| Equity/assets ratio, % | 51.1 | 48.0 | 51.0 |
|---|---|---|---|
| Total assets | 3,500,148 | 3,190,365 | 3,756,229 |
| Equity | 1,789,636 | 1,532,235 | 1,916,825 |
| SEK thousand | Oct 31, 2025 |
Oct 31, 2024 |
Apr 30, 2025 |
Shows the portion of assets financed with equity. This measure is used for the purpose of management by objectives in the operations.
Equity divided by total assets on the balance-sheet date.
| SEK thousand | Oct 31, 2025 |
Oct 31, 2024 |
Apr 30, 2025 |
|---|---|---|---|
| Total assets | 3,500,148 | 3,190,365 | 3,756,229 |
| Non-interest-bearing liabilities | 1,603,476 | 1,566,221 | 1,740,213 |
| Capital employed | 1,896,672 | 1,624,144 | 2,016,016 |
Shows the portion of the company's assets that has been borrowed from, for example, the company's owners or external lenders, and shows the company's profitability in relation to externally financed capital and equity.
Total assets reduced by non-interest-bearing liabilities.
Growth in operating profit per share over a five-year period
| SEK | 12 months Nov 2024 –Oct 2025 |
Full-year May–Apr 2024/2025 |
|---|---|---|
| Operating profit per share before dilution | 4.262 | 3.752 |
| Operating profit per share before dilution five years earlier | 1.768 | 1.534 |
| Growth in operating profit per share before dilution | _ | |
| over a five-year period, % | 141.1 | 144.6 |
Shows the growth of the operations over a five-year period. This measure is used for the purpose of management by objectives in the operations. Disclosures and adjustments of the effects of non-recurring transactions in operating profit and operating margin are made separately. When applicable, information about such transactions is provided on page 1.
Operating profit per share on the balance-sheet date less operating profit per share on the balance-sheet date five years earlier divided by operating profit per share on the balance-sheet date five years earlier.
Profit margin
| SEK thousand | 3 months Aug-Oct |
3 months Aug-Oct |
6 months May–Oct |
6 months May–Oct |
12 months Nov 2024 |
Full-year May–Apr |
|---|---|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | –Oct 2025 | 2024/2025 | |
| Profit after financial items | 186,441 | 110,527 | 316,741 | 211,787 | 831,235 | 726,281 |
| Net sales | 850,583 | 753,500 | 1,616,437 | 1,477,336 | 3,378,912 | 3,239,811 |
| Profit margin, % | 21.9 | 14.7 | 19.6 | 14.3 | 24.6 | 22.4 |
Shows a comparison of profitability regardless of corporate tax
Profit after financial items divided by net sales.
| 6 months | 6 months | 12 months | Full-year | |
|---|---|---|---|---|
| Oct 31, | Oct 31, | Oct 31, | Apr 30, | |
| 2025 | 2024 | 2025 3 | 2025 3 | |
| Contracted order bookings, SEK million | 4,741.2 | 4,838.1 | 8,609.2 | 8,706.1 |
| of which guaranteed order bookings, SEK million | 3,438.3 | 4,560.1 | 6,531.2 | 7,653.0 |
| Operating margin, % | 19.0 | 14.2 | 24.3 | 22.3 |
| Profit margin, % 3 | 19.6 | 14.3 | 24.6 | 22.4 |
| Average no. of employees | 1,321 | 1,224 | 1,298 | 1,249 |
| Cash flow per share, SEK 1,2 | 0.83 | 0.62 | 5.00 | 4.79 |
| P/E ratio, multiple | n/a | n/a | 90.1 | 101.6 |
| Share price at end of period, SEK | 301.80 | 283.00 | 301.80 | 296.60 |
| Return on equity, % | 13.6 | 10.8 | 38.9 | 32.3 |
| Return on capital employed, % | 16.4 | 13.2 | 47.6 | 40.4 |
| Equity/assets ratio, % | 51.1 | 48.0 | 51.1 | 51.0 |
| Liquidity ratio, multiple | 1.7 | 1.6 | 1.7 | 1.7 |
| Equity per share, SEK 2 | 9.29 | 7.95 | 9.29 | 9.95 |
<sup>1 Cash flow from operations. 2 Before and after dilution. 3 The outcomes for R12 and full-year 2024/2025 include a positive effect from a patent settlement, a non-recurring transaction.
<-- PDF CHUNK SEPARATOR -->
| SEK million | 20 | 25/2026 | 25/2026 2024/2025 | 2023/2024 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 | Q1 | Q4 | Q3 1 | Q2 | Q1 | Q4 | Q3 | Q2 | Q1 | ||
| Net sales | 850.6 | 765.9 | 914.1 | 848.4 | 753.5 | 723.8 | 898.1 | 694.0 | 787.7 | 583.7 | |
| Capitalized work for own use | 27.6 | 23.0 | 18.9 | 22.9 | 19.4 | 12.9 | 16.3 | 19.3 | 17.9 | 18.0 | |
| Other operating income | 25.3 | 7.1 | 14.5 | 202.6 | 6.5 | 2.7 | 1.3 | 0.6 | 2.2 | 1.3 | |
| Operating expenses | -686.0 | -649.6 | -719.8 | -729.9 | -642.5 | -613.5 | -687.0 | -614.9 | -607.5 | -509.2 | |
| Depreciation/amortization and impairment | -28.9 | -27.6 | -28.8 | -29.3 | -27.3 | -26.1 | -31.3 | -24.7 | -23.6 | -24.5 | |
| Operating profit | 188.6 | 118.8 | 198.9 | 314.7 | 109.6 | 99.8 | 197.4 | 74.4 | 176.7 | 69.3 | |
| Total financial items | -2.2 | 11.5 | -16.9 | 17.8 | 0.9 | 1.5 | 14.7 | -1.5 | 13.6 | 8.2 | |
| Profit after financial items | 186.4 | 130.3 | 182.0 | 332.5 | 110.5 | 101.3 | 212.1 | 72.9 | 190.3 | 77.5 | |
| Tax on earnings for the period | -38.0 | -27.5 | -50.8 | -68.5 | -22.7 | -20.9 | -53.6 | -15.1 | -39.7 | -16.0 | |
| Profit for the period | 148.4 | 102.8 | 131.2 | 264.0 | 87.8 | 80.4 | 158.5 | 57.8 | 150.6 | 61.6 |
$^{\rm 1}$ The outcomes include positive effects from a patent settlement, a non-recurring transaction.
| 05/0000 | 0.4/0005 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 20 | 25/2026 | 20 | 24/2025 | 20 | )23/2024 | |||||
| Q2 | Q1 | Q4 | $Q3^2$ | Q2 | Q1 | Q4 | Q3 | Q2 | Q1 | |
| Contracted order bookings, SEK | ||||||||||
| million | 3,431.6 | 1,309.5 | 2,900.3 | 967.6 | 4,223.1 | 615.0 | 896.9 | 1,853.6 | 503.0 | 2,970.0 |
| of which guaranteed order bookings | 2,246.0 | 1,192.3 | 2,382.1 | 710.8 | 4,017.0 | 543.1 | 762.3 | 1,652.5 | 460.1 | 344.4 |
| u | 2,240.0 | 1,192.3 | 2,302.1 | 110.0 | 4,017.0 | 343.1 | 102.3 | 1,002.0 | 400.1 | 344.4 |
| Recurring revenue, SEK million | 587.9 | 549.2 | 574.6 | 525.8 | 484.7 | 482.3 | 463.5 | 434.7 | 429.6 | 397.2 |
| of which cloud services (CRR) | 212.2 | 179.4 | 184.1 | 162.8 | 121.3 | 122.8 | 113.8 | 103.2 | 93.4 | 86.4 |
| Operating margin, % | 22.2 | 15.5 | 21.8 | 37.1 | 14.5 | 13.8 | 22.0 | 10.7 | 22.4 | 11.9 |
| Earnings per share, SEK 1 | 0.77 | 0.53 | 0.68 | 1.37 | 0.46 | 0.42 | 0.82 | 0.30 | 0.78 | 0.32 |
| Cash flow per share, SEK 1 | 0.22 | 0.61 | 1.15 | 3.01 | 0.91 | -0.29 | 0.69 | 1.21 | 0.30 | -0.51 |
| Return on equity, % | 7.7 | 5.2 | 7.0 | 15.8 | 5.5 | 5.0 | 10.7 | 4.2 | 11.0 | 4.6 |
| Return on capital employed, % | 9.3 | 6.3 | 9.4 | 18.9 | 6.7 | 6.2 | 14.2 | 5.3 | 13.5 | 5.5 |
| Equity/assets ratio, % | 51.1 | 54.5 | 51.0 | 46.7 | 48.0 | 52.2 | 48.9 | 49.2 | 49.8 | 50.8 |
| Equity per share, SEK 1 | 9.29 | 10.62 | 9.95 | 9.40 | 7.95 | 8.59 | 8.15 | 7.20 | 6.96 | 7.20 |
| Share price at end of period, SEK | 301.8 | 363.0 | 296.6 | 254.0 | 283.0 | 243.4 | 219.2 | 195.1 | 120.6 | 168.6 |
Before and after dilution. 2 The outcomes include positive effects from a patent settlement, a non-recurring transaction.
Five-year summary
| 2024/2025 2 | 2023/2024 | 2022/2023 | 2021/2022 | 2020/2021 | |
|---|---|---|---|---|---|
| Contracted order bookings, SEK million | 8,706.1 | 6,223.5 | 4,635.7 | 2,320.2 | 2,651.6 |
| Net sales, SEK million | 3,239.8 | 2,963.6 | 2,350.8 | 1,949.1 | 1,632.4 |
| Operating profit, SEK million | 723.0 | 517.8 | 455.7 | 383.4 | 350.1 |
| Profit after financial items, SEK million | 726.3 | 552.8 | 479.4 | 394.5 | 348.2 |
| Profit for the period, SEK million | 563.4 | 428.4 | 375.0 | 314.8 | 275.5 |
| Operating margin, % | 22.3 | 17.5 | 19.4 | 19.7 | 21.4 |
| Profit margin, % | 22.4 | 18.7 | 20.4 | 20.2 | 21.3 |
| Earnings per share before dilution, SEK 1 | 2.92 | 2.22 | 1.95 | 1.63 | 1.43 |
| Earnings per share after dilution, SEK 1 | 2.92 | 2.22 | 1.95 | 1.63 | 1.43 |
| Dividend/redemption program per share, SEK 1,3 | 2.10 | 1.10 | 1.10 | 1.00 | 0.90 |
| Share price at end of year, SEK 1 | 296.60 | 219.20 | 161.70 | 124.80 | 121.00 |
| P/E ratio, multiple | 101.6 | 98.7 | 82.9 | 76.6 | 84.6 |
| Return on equity, % | 32.3 | 29.9 | 31.5 | 31.9 | 32.2 |
| Return on capital employed, % | 40.5 | 37.3 | 38.2 | 37.5 | 37.4 |
| Equity per share before dilution, SEK 1 | 9.95 | 8.15 | 6.73 | 5.61 | 4.65 |
| Equity per share after dilution, SEK 1 | 9.95 | 8.15 | 6.73 | 5.61 | 4.65 |
| Equity/assets ratio, % | 51.0 | 48.9 | 47.4 | 49.3 | 54.2 |
<sup>1 Comparative figures per share have been restated due to the 5:1 share split that Sectra carried out in the second quarter of 2021/2022.
2 The outcomes include positive effects from a patent settlement, a non-recurring transaction.
3 The amount for 2024/2025 includes an extraordinary dividend of SEK 1.00.
Exchange rates
| Currency | Average rates in SEK | Closing rates in SEK | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 3 months Aug–Oct 2025 |
3 months Aug–Oct 2024 |
Δ % |
6 months May–Oct 2025 |
6 months May–Oct 2024 |
Δ % |
Oct 31, 2025 |
Oct 31, 2024 |
Δ % |
|
| US dollar, 1 USD | 9.38 | 10.27 | -8.7 | 9.46 | 10.45 | -9.5 | 9.36 | 10.56 | -11.4 |
| Euro, 1 EUR | 10.94 | 11.31 | -3.3 | 10.96 | 11.38 | -3.7 | 10.84 | 11.45 | -5.3 |
| British pound, 1 GBP | 12.55 | 13.56 | -7.4 | 12.72 | 13.55 | -6.1 | 12.33 | 13.77 | -10.5 |
A standard communication protocol used to capture, store and transfer medical images and related data.
A process for determining genetic material, DNA, in a sample.
The study of genetic material, meaning an organism's DNA. In medicine, a patient's genetic material is studied to increase understanding of the causes of disease. In cancer diseases, for example, a tumor's mutations are studied in DNA. The genetic information plays an important role in diagnosing cancer and customizing treatment, known as precision medicine.
The field of medicine dealing with the functions and diseases of the heart.
Basic infrastructure that is essential for the functioning of society, such as roads, bridges and electricity and water supply.
Equipment that uses mathematical manipulations (algorithms and keys) to encrypt information, so that it can be interpreted or read only by the intended recipient. To read encrypted information, the recipient must have the correct key and algorithm.
From the term cloud computing, meaning delivering services and sharing IT infrastructure over the internet.
A specialist medical area for the diagnosis and treatment of eye disorders.
A surgical specialty for disorders affecting the musculoskeletal system.
A specialized medical area that uses tissues and body fluids for diagnostic purposes.
Providing patient care that is highly adapted to individual conditions. Advanced diagnostic analyses are a cornerstone of precision medicine.
A health science discipline and medical specialty that uses technologies for imaging the human body, such as X-ray, magnetic resonance imaging (MRI) and ultrasound.
A subscription for Sectra's enterprise imaging solution. Under the new model, customers pay a more evenly distributed subscription fee every year instead of paying a higher license fee for software at the start of the contract and a lower rolling service fee. The fee is determined based on the functionality used and the number of different services utilized. When Sectra One is sold as fully cloud-based services, it is referred to as Sectra One Cloud.
Cryptographic methods and other measures designed to prevent unauthorized parties from accessing or influencing information in telecom and IT systems. The high assurance products that Sectra provides are approved by one or more nations and, for certain products, by the EU and NATO.
To contribute to a healthier and safer society.
To increase the effectiveness of healthcare, while maintaining or increasing the quality of care.
To strengthen the stability and efficiency of society's most important functions through solutions for critical IT security.
Imaging IT Solutions helps hospitals across the world to become more efficient, enabling them to care for more patients and save more lives. Increased use of medical images and aging populations that are living longer pose huge challenges to healthcare. Sectra's IT solutions and services for medical diagnostic imaging enable greater efficiency and contribute to healthcare advancements. Sectra has exceeded 2,500 installations of medical IT systems, and customers include some of the largest healthcare providers in the world.
Secure Communications helps society's critical functions, government officials and diplomats to use modern technology to exchange information securely, thereby contributing to a stable and secure society. Sectra's solutions and services increase cybersecurity by protecting some of society's most sensitive information and communications. Several of the business area's products are approved by the EU, NATO, and national security authorities.
Business Innovation gathers smaller activities that could eventually lead to major growth in Sectra's main areas or related niches.
Customers and customer satisfaction are always assigned top priority to enable long-term growth. Close relationships with demanding customers ensure that Sectra's solutions meet market demands for quality, functionality and usability.
A corporate culture that motivates and inspires the company's employees to solve customer problems and constantly drive improvement. All so we can meet—and in many cases exceed—customer expectations.
Close cooperation with customers, universities and industrial partners in order to identify needs and ideas, combined with a corporate culture where management encourages the employees to test out new ideas and projects.
International expansion mainly in areas and regions where Sectra holds an established position. Expansion is primarily to be achieved through organic growth, in certain cases supplemented by acquisitions that strengthen the Group's organic growth.
For more information, visit https://investor.sectra.com

IT for healthcare and cybersecurity for critical social functions are rapidly changing markets that society needs to invest in. This creates major growth opportunities for companies such as Sectra.
Sectra has an over 45-year history of growth and profitability. Over 50% of the company's sales comprise recurring revenue from long-term customer contracts.
A strong corporate culture clearly focused on customer value and employees who are passionate about making a difference lead to satisfied customers. To safeguard our corporate culture, growth is primarily organic.
Sectra is an established brand in niche areas where trust and stable products are highly important success factors. We have a multinational reach, with thousands of customers worldwide.
By continuously investing in new and enhanced products and services, as well as how they are packaged and delivered, we create value for our customers. We also have a self-financed portfolio of research and business projects with the potential to add significant value in the future.
Contributing to healthier and safer societies is the foundation of Sectra's operations and business model. Helping our customers improve the efficiency and quality of patient care and increase cybersecurity in critical social functions is our most significant contribution to a sustainable society.
The principal owners, who have been part of the company since the 1980s, have firm dedication to the long-term development of the company, and all members of Group Management are shareholders.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.